Safety of Oral Dofetilide for Rhythm Control of Atrial Fibrillation and Atrial Flutter.

Link to article at PubMed

Related Articles

Safety of Oral Dofetilide for Rhythm Control of Atrial Fibrillation and Atrial Flutter.

Circ Arrhythm Electrophysiol. 2015 Jun 10;

Authors: Abraham JM, Saliba WI, Vekstein C, Lawrence D, Bhargava M, Bassiouny M, Janiszewski D, Lindsay BD, Militello M, Nissen SE, Poe S, Tanaka-Esposito C, Wolski K, Wilkoff BL

BACKGROUND: -Although dofetilide is widely used in the United States for rhythm control of atrial fibrillation (AF), there is limited post-approval safety data in the AF population despite its known risk of Torsade de pointes (TdP).
METHODS AND RESULTS: -We conducted a retrospective chart review of a cohort of 1,404 patients initially loaded on dofetilide for AF suppression at the Cleveland Clinic from 2008-2012 to evaluate the incidence and risk factors for in-hospital adverse events as well as the long-term safety of continued use. Of the 17 patients with TdP during loading (1.2%), 10 had a cardiac arrest requiring resuscitation (one death), 5 had syncope/pre-syncope and 2 were asymptomatic. Dofetilide loading was stopped for 105 patients (7.5%) due to QTc prolongation or TdP. Variables correlated with TdP were 1) female gender, 2) 500 mcg dose, 3) reduced ejection fraction, and 4) increase in QTc from baseline. One-year all-cause mortality was higher in patients who continued dofetilide compared to those who discontinued use (HR 2.48, 95%CI 1.08 to 5.71, p=0.03). Those patients who had a TdP event had higher one-year all-cause mortality than those who did not (17.6% vs. 3% at one year, p<0.001).
CONCLUSIONS: -Dofetilide loading has a low but finite risk of TdP and other adverse events that warrant the current FDA-mandated practice of inpatient monitoring during drug loading. In this cohort, all-cause mortality was higher at one year in those patients continued on dofetilide as well as in those patients who experienced TdP while loading.

PMID: 26063741 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *